Cell and Tissue Preservation Market Trends, Leading Companies, Company Revenue / Sales Performance, Procedure Volume, Healthcare Spending, Technology Adoption, Reimbursement Analysis, Competitive Landscape, and Growth Outlook

Revenue, 2026

USD 5.77 Bn

Forecast Year, 2035

USD 14.13 Bn

CAGR, 2026 - 2035

8.31%

Report Coverage

Global

Cell and Tissue Preservation Market Size and Forecast 2026 to 2035

The global cell and tissue preservation market size was valued at USD 5.77 billion in 2026 and it is expected to hit over USD 14.13 billion by 2035 with a remarkable CAGR of 8.31% from 2026 to 2035.

Cell and Tissue Preservation Market Key Takeaways

• North America led the global market with the highest market share of 41% in 2025.
• By type, the cell segment has held the largest market share of 53% in 2025.
• By application, the therapeutics segment captured the biggest revenue share of 40% in 2025.
• By product, the equipment segment registered the maximum market share in 2025.
• By end user, the biobanks segment generated over 68% of revenue share in 2025.

Cell and Tissue Preservation Market Growth Factors

The global cell and tissue preservation market is significantly driven by the rising preservation of stem cells. The rising investments towards the development of healthcare infrastructure, adoption of smart technologies, and medical innovations are expected to foster the market growth during the forecast period. The globe is witnessing an increasing prevalence of various chronic diseases such as cardiovascular diseases, range of malignancies, diabetes, neurological disorders, and many other diseases, which is significantly boosting the growth of the global cell and tissue preservation market. The improved access to the better healthcare facilities owing to the rising disposable income, presence of developed healthcare infrastructure, and rising healthcare expenditure has led to the development of innovative bio-preservation technologies and facilities.

The adoption of the cryopreservation helps to extend the shelf life of some of the cells. The recent outbreak of the COVID-19 pandemic in 2020 has forced the companies to focus on reducing the risks of cross contamination especially at the fertility clinics and centers. The increasing demand for the regenerative therapies across the globe is expected to fuel the growth of the cell and tissue preservation market. The regenerative therapies helps in the restoration of the cells and tissues caused due to the age related diseases, congenital abnormalities, and injuries. Furthermore, the growing demand for storing organs for transplantation is another major factor that is anticipated to have a significant impact on the market growth in the foreseeable future.

Market Scope

Segments Insights

Type Insights

Based on the type, the cell segment led the global cell and tissue preservation market in 2025 with revenue share of 53% with a CAGR of 11.7% from 2026 to 2035. The rising demand for the cell therapies and regenerative therapies among the patients is expected to drive the market growth. Furthermore, the increasing prevalence of various diseases and the rising investments in the technological advancements to enhance the storage systems of cells is propelling the growth of this segment.

Tissue Segment is expected to be the fastest-growing segment during the forecast period. This growth is attributed to the increasing penetration of the biobanks across the globe. Furthermore, the rising demand for the regenerative medicines is significantly fostering the growth of this segment. The rising incidences of age related diseases and severe injuries are propelling the demand for the tissue preservation across the globe. The rising geriatric population across the globe is expected to further spur the growth of this segment in the forthcoming years. According to the United Nations, the elderly population across the globe is expected to reach around 2 billion by the year 2050, which will positively contribute towards the growth of the tissues segment in the cell and tissue preservation market.

Application Insights

On the basis of application, the therapeutics was the dominating segment that constituted revenue of around 40% in 2025 with a CAGR of 11.8% during the forecast period. The increased demand for the cell and tissue preservation for the development of therapeutics to cure various chronic and non-communicable diseases has led to the dominance of this segment across the globe. The rapidly surging prevalence of lifestyle and age related diseases is expected to foster the growth of this segment and is expected to sustain its position in the global cell and tissue preservation market throughout the forecast period.

IVF treatment segment is anticipated to exhibit highest CAGR during the forecast period. This is attributed to the rising demand for the IVF treatments across the globe. Late marriages, rising participation of women in workforce, higher preference to career over marriage, and several other factors are resulting in the declining fertility rates and growing complexities in the pregnancies. These factors are propelling the demand for the IVF treatment, which in turn is expected to drive the growth of the IVF treatment segment in the cell and tissue preservation market.

Product Insights

Depending on the product, the global cell and tissue preservation market was dominated by the equipment segment in 2025. The surging demand for the biobanks across the globe owing to its higher utilization in tissue, stem cell, Plasma, and DNA research has fueled the growth of the equipment segment. The equipment segment was valued at US$ 2,026 million in 2023 and it is expected to hit US$ 6,805 million in 2033, growing at a CAGR of 11.7% from 2024 to 2033. The increased adoption of the freezing and storage systems for the preservation of cells and tissues has led to the dominance of this segment in the global market. Furthermore, the high costs associated with the acquisition of the advanced and innovative equipment helped in the higher revenue generation.

Software segment is anticipated to be the most opportunistic segment during the forecast period. This rising investments in the adoption of software technologies owing to the rising trend of digitization and automation. The increasing needs for controlling costs and effectively manage the operations and inventories have fueled the adoption of the software technologies in the biobanks.

End User Insights

Based on the end user, the biobanks segment led the global cell and tissue preservation market accounting for over 68% of the market share in 2025. The rising demand for the stem cell preservation among the researchers has significantly fueled the growth the biobanks segment. Moreover, the rising advancements in the technology and growing investments in the research activities for the purpose of drug discovery and development of various therapeutics is further expected to drive the market growth.

The biobanks is also anticipated to be the fastest-growing segment during the forecast period. The surging number of egg and sperm banks and the rising adoption of the assisted reproductive technology is fueling the growth of the biobanks segment.

Regional Insights

Why Does North America Lead the Cell and Tissue Preservation Market?

North America was the leading cell and tissue preservation market in 2025. The demand for the advanced healthcare technology is higher in North America. The presence of advanced healthcare infrastructure and higher government investments in the research and development in the healthcare technology has significantly driven the growth of the cell and tissue preservation market. The increased prevalence of chronic diseases among the population of US has attracted heavy investments in drug discovery and development of innovative therapeutics, which has driven the growth of the North America cell and tissue preservation market.

U.S. Cell and Tissue Preservation Market Size and Growth 2026 to 2035

The U.S. cell and tissue preservation market size was estimated at USD 1.48 billion in 2025 and is predicted to be worth around USD 4.50 billion by 2035 at a CAGR of 11.95% from 2026 to 2035.

Why Is Asia Pacific the Fastest-Growing Cell and Tissue Preservation Market?

Asia Pacific is expected to be the most opportunistic market during the forecast period. The increasing investments in development of advanced healthcare and medical infrastructure and the presence of several top pharmaceutical companies and research organizations are significantly contributing towards the growth of the Asia Pacific cell and tissue preservation market.

Competitive Landscape

The cell and tissue preservation market is emerging with advances in the healthcare sector. Consistent research and development for a range of biological innovations is capturing a mature layer of safety in the storage operation. The temperature tactics are spurring demand from healthcare leaders for real-time drug delivery and treatment. The market giants such as Lonza, Chart Industries, BioLife Solutions, Thermo Fisher Scientific and Merck KGaA are the backbone of the market development and evolution.

Company Profiles

Lonza

• HQ: Basel, Switzerland.
• Founded: 1897
• Ownership: CDMO.
• Business Overview: The Lonza business focuses on delivering customized services to the nutrition, biotechnology and pharmaceutical industries. Its commendable specialized service model is an asset benefiting the company's revenue.
• Products: Unified Biologics, small molecules, modern synthesis, bioscience research solutions, and specialized models
• Geographic Presence: The company operates across Asia, North America and Europe.
• Revenue: Lonza earned the profit of CHF 6.5 billion with a 31.6% EBITDA margin.
• Recent Development: In August 2026, Lonza introduced its best-in-class custom media prototyping service to support bioprocess development. The services will be a companion to the bio innovations and a strength to the biopharmaceutical companies.
• Key Strategies: The company serves as a center of specialized portfolio for the modern therapies involving talk of the healthcare town, the gene and cell therapy that highly relies on massive cells.

Chart Industries

• HQ: Georgia 30107, United States.
• Founded: 1992
• Ownership: A gas, air, tools and process technologies Provider.
• Business Overview: Chart aims to expand its portfolio for cold boxes, water treatment and LNG. The powerful systems and technologies are a plus for the company's business strategy expansion. Chart focuses on delivering clean energy solutions and healthcare storage operations.
• Products: ISO Containers, Bulk Storage Tanks, and Cold Boxes.
• Geographic Presence: The company operates over 64 manufacturing facilities and around 50 service locations across South America, India, Asia, the Americas, Australia, and Europe.
• Revenue: The 2025 revenue was confirmed at $4.26 billion and is leading with $884.8 million in the running 2026.
• Recent Development: In July 2026, Baker Hughes announced conditional approval for the Chart acquisition. The approval is tied to the professional promises and compliance for clarity and robust business.
• Key Strategies: The company continue to bolster its equipment, liquid, gas and business to fit the responsible industry needs, such as the medical sector.

BioLife Solutions

• HQ: Bothell, Washington.
• Founded: 1987
• Ownership: Services and Tools provider for the cell and gene therapy sector.
• Business Overview: The business continues with the mission of supporting and providing essential cell solutions to advance cell and gene therapy, aligned with healthcare development and growth.
• Products: Customized freeze media, shipping media and hypothermic storage.
• Geographic Presence: The company operates across
• Revenue: The company's revenue is expected to reach $28.47 million following the 2025 profit of $96.2 million.
• Recent Development: In August 2026, Repligen came forward with the purchasing deal for BioLife Solutions, with the addition of CryoStor biopreservation to bolster its bioprocessing portfolio. This $1.5bn deal is a smart strategy for business hype after learning the manufacturing integration transitions and trends.
• Key Strategies: The company's strategy is dedicated to serving best-in-class bioproduction tools and a robust range of services for retaining its position in the advanced medical sector.

Thermo Fisher Scientific

• HQ: Massachusetts, 02451, United States.
• Founded: 1902
• Ownership: Service, software, lab tools and scientific instruments provider.
• Business Overview: The company runs as a comprehensive solution for healthcare and pharmaceuticals. The business is a consistent chain meeting the massive demand from the clinical sector for purified reagents, solvents and other major services as well.
• Products: lab shakers, electron microscopes, chromatography systems, etc.
  Geographic Presence: Thermo operates its offices across EMEA, APAC and the Americas, including its 600-site footprint in the market.
• Revenue: Thermo's revenue in 2025 was $44.56 billion, and in the ongoing year 2026 it is expected to increase by 10% ($11.99 billion).
• Recent Development: In July 2026, Thermo Fisher introduced a new branded Spectrophotometer portfolio for the testing of life, water and food. The testing volume has been exceeding, and so this suite will be a strong backing in the lab setting.
• Key Strategies: The long-standing strategy of Thermo is to stay connected with the advanced healthcare needs and bolster life sciences and specialized diagnostics for a healthy future of the patient population.

Merck KGaA

• HQ: Darmstadt, Germany.
• Founded: 1668
• Ownership: Chemical and Pharmaceutical Family-owned Company (Merck Family).
• Business Overview: The business is connected to electronics, life sciences and medical that aims to serve a healing formula for infertility, cancer and multiple sclerosis. Company concentartes on life sciences needs as well as production services, lab content, etc.
• Products: Sigma-Aldrich, specialty gases, metrology systems, thin films, etc.
• Geographic Presence: The company operates across 66 countries with around 60,000 employees.
• Revenue: In 2025, Merck successfully earned €21.1 billion and increased its sales by 3.4%.
• Recent Development: In August 2026, Merck showed a level of confidence by updating the sales prediction for 2026 (Q2) due to its reach in the healthcare sector over the years. The expansion of rare conditions is another profit for the company.
• Key Strategies: The strategy of enhancing its current technologies and branded solutions to meet modern medical needs is nearly a milestone for the company.

Cell and Tissue Preservation Market Companies

• Thermo Fisher Scientific, Inc.
• Lonza
• BD
• MerckKGaA
• Cytiva
• Agilent Technologies, Inc.
• Avantor, Inc.
• FUJIFILM Irvine Scientific
• BioLifeSolutions Inc.
• AMSBIO
• Princeton CryoTech
• STEMCELL Technologies Inc.
• LGC SeraCare
• Corning Incorporated
• CellGenix GmbH

Segments Covered in the Report

By Type

• Cell
• Mammalian Cells
• Others (Microorganisms and Plant Cells)
• Tissue
• Blood
• Bone
• Soft Tissues
• Skin
• Others

By Application

• Therapeutics
• Drug Discovery
• Gene therapy
• IVF treatment
• Cell therapy
• Research & Development

By Product

• Equipment
• Freezers
• Refrigerators
• Storage Systems
• Others
• Software
• Bio-preservation Media
• Home-brew Media
• Pre-formulated Media

By End User

• Biobanks
• Hospitals

By Cell Provider

• CD34+
• CD19+
• MSC
• iPSC
• hESC
• Tumor Cells
• Others

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa